Enhancing cancer treatment personalization by combining paired tumor and normal DNA sequencing with transcriptome analysis for targeted therapy identification

In the past, cancer testing mainly looked at tumor DNA to find mutations. These mutations helped decide which drugs might work. But testing only tumor DNA can be tricky. It can be hard to tell if a mutation is only in the tumor or if it is inherited and found in all the patient’s cells. This can cause mistakes in finding true mutations.

Paired tumor-normal DNA sequencing tests both the tumor DNA and normal DNA from the same patient, like from blood cells. Comparing these helps remove inherited mutations from tumor results. A study with 500 patients showed this method lowered false-positive mutation findings by about 28% compared to tumor-only tests. This accuracy is important to choose the right targeted treatments and avoid wrong therapies.

The Tempus xT platform uses this method by testing 648 genes related to solid tumors in both tumor and normal DNA. It checks for different kinds of mutations and instability in DNA. Doctors can use this information to pick more precise treatments based on the patient’s cancer genetics.

The Added Value of Transcriptome (RNA) Sequencing

DNA tests show which genes have mutations, but not all mutations change how a tumor behaves. RNA sequencing examines messenger RNA to see which genes are active and making proteins. This method can find gene fusions, alternative gene forms, and non-coding RNA that DNA tests might miss but that affect tumor growth and treatment response.

Studies show adding RNA sequencing to paired tumor-normal DNA testing improves finding targets for treatment. For example, RNA sequencing raised gene fusion detection by 29% compared to DNA alone. Gene fusions are targets for some cancer drugs, especially for rare cancers.

RNA tests also help classify cancers better. In one study, combining DNA and RNA sequencing with tests for immune markers raised the correct therapy match rate from 29.6% to 43.4%. This shows RNA data gives doctors more treatment options.

Improving Clinical Trial Matching with Integrated Molecular Profiling

Besides approved treatments, clinical trials offer new experimental options. Matching patients to the right trial is important, especially for cancers that do not respond well to usual care.

Molecular profiling that includes paired tumor-normal DNA, RNA data, and immune markers helps match patients to clinical trials better. Around 76.8% of patients in studies were linked to at least one trial based on their tumor and biomarker data. The Tempus platform helps with this by using big databases of research and clinical data.

For hospital administrators and IT staff, using these profiling tools can improve cancer programs. It helps recruit patients for trials and supports research collaborations.

Role of Multi-Omics Integration in Personalized Cancer Care

Multi-omics means looking at many types of biological information like DNA, RNA, proteins, and metabolites from one patient. This is important because cancer involves many complex molecular changes.

Using just one type of data can miss key points. DNA alone does not show gene activity. RNA alone may miss some mutation causes. Combining different data types gives a better understanding of the tumor. This leads to better cancer classification and prediction of how treatments will work.

Healthcare administrators should know that multi-omics is the future of personalized cancer care. But it also brings challenges. Hospitals need to plan for proper sample handling, data systems that can merge different kinds of data, and people trained to understand complex results. Even with these challenges, investing in these methods could improve patient results.

The Significance of Liquid Biopsy Combined with Paired Sequencing

Liquid biopsy tests tumor DNA circulating in the blood. It is less invasive and can be done repeatedly to watch how the tumor changes over time.

A study with 1,448 patients found that 9% had important mutations seen only in liquid biopsies but not in tumor tissue tests. Combining liquid biopsy with paired DNA sequencing gives a fuller picture of the tumor’s changes. It also helps monitor leftover disease and response to treatment.

For IT managers and administrators, using liquid biopsy means managing samples from both tissue and blood. It also means handling data from several sources and merging results in medical records. This method can lower patient discomfort and allow closer monitoring without many invasive procedures.

Integration of Clinical Data and Guidelines for Enhanced Treatment Decisions

Molecular data by itself is not enough. It must be combined with current clinical information like patient history, treatment effects, and other health issues.

Platforms like Tempus Smart Reporting combine molecular data with clinical records and knowledge from guidelines such as OncoKB and NCCN. This helps make personalized treatment choices, find possible drug resistance, and show relevant clinical trials.

Almost 96% of patients can be matched to clinical trials when molecular and clinical data are combined. This shows how important clinical context is for using molecular information.

Healthcare administrators should look for platforms that support real-time decisions, help improve quality of care, and stay up-to-date with clinical standards.

AI and Automation to Support Genomic Workflows in Cancer Care

Testing tumor and normal DNA, RNA, liquid biopsies, and clinical data creates a lot of information. Artificial intelligence (AI) helps automate and organize this work.

AI-Driven Clinical Assistants
AI tools like Tempus One work with electronic health records to let doctors quickly access patient molecular data. This helps with choosing treatments without reading all raw data. AI combines molecular and clinical data to suggest treatments and clinical trials.

Algorithmic Data Interpretation
Smart AI programs analyze multi-omics data. They reduce false mutation findings and spot important variants like rare gene fusions. AI learns from millions of records to improve treatment predictions.

Workflow Automation
Automation helps with ordering tests, tracking samples, and making reports. Electronic connections with labs and scheduling reduce paperwork. AI can flag urgent cases and suggest team reviews.

Benefits for US Healthcare Practices
In the US, where many patients get treated and billing is complex, AI and automation make work faster and safer. Practice owners and IT teams benefit by lowering errors, speeding reports, and improving patient satisfaction with timely care.

Considerations for US Healthcare Administrators and IT Managers

• Data Integration and Security: Managing multi-omics and clinical data needs safe systems that follow HIPAA rules. Systems must work well between labs, clinics, and research databases.
• Cost and Resource Planning: Using these molecular tests and AI costs more upfront. Administrators should consider budgets, reimbursement, and returns through better outcomes and trial access.
• Staff Training and Education: Doctors and staff need to learn about paired tumor-normal sequencing and RNA testing benefits and limits. IT teams need training to run AI tools and data systems well.
• Collaboration with External Partners: Working with companies like Tempus, which provide molecular and AI platforms, can help hospitals adopt these technologies faster without building everything inside.

Closing Remarks

Using paired tumor and normal DNA sequencing combined with RNA sequencing brings progress to cancer care in the United States. This method helps find true mutations more accurately, identifies better treatment targets, and matches patients to clinical trials more effectively. Adding AI tools helps automate testing and decision-making in complex molecular work.

Those who manage cancer care programs, like healthcare administrators, practice owners, and IT managers, can gain by understanding and using these methods. This can lead to better personalized care for cancer patients and prepare organizations for future needs of precision medicine.